共 1 条
[1]
Carrat F, 2021, INT J EPIDEMIOL, V50, P1458, DOI 10.1093/ije/dyab110
Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study (vol 50, pg 1458, 2021)
被引：2
作者：
Carrat, Fabrice
de lamballerie, Xavier
Rahib, Delphine
Blanche, Helene
Lapidus, Nathanael
Artaud, Fanny
Kab, Sofiane
Renuy, Adeline
de Edelenyi, Fabien Szabo
Meyer, Laurence
Lydie, Nathalie
Charles, Marie-Aline
Ancel, Pierre-Yves
Jusot, Florence
Rouquette, Alexandra
Priet, Stephane
Villarroel, Paola Mariela Saba
Fourie, Toscane
Lusivika-Nzinga, Clovis
Nicol, Jerome
Legot, Stephane
Druesne-Pecollo, Nathalie
Esseddik, Younes
Lai, Cindy
Gagliolo, Jean-Marie
Deleuze, Jean-Francois
Bajos, Nathalie
Severi, Gianluca
Touvier, Mathilde
机构：
[1] Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris
[2] Département de Santé Publique, APHP.Sorbonne Université, Paris
[3] Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection, Marseille
[4] Santé Publique France, Saint-Maurice
[5] Fondation Jean Dausset-CEPH, Centre d'Etude du Polymorphisme Humain, CEPH-Biobank, Paris
[6] CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif
[7] Paris University, Paris
[8] Paris-Saclay University, Inserm UMS 11, Villejuif
[9] Sorbonne Paris Nord University, Inserm U1153, INRAE U1125, CNAM, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, University of Paris, CRESS, Bobigny
[10] Université Paris-Saclay, Inserm, CESP U1018, Le Kremlin Bicêtre
[11] Service de Santé Publique, APHP.Paris Saclay, Le Kremlin Bicêtre
[12] Ined, Inserm, EFS, UMS Elfe, Aubervilliers
[13] Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité, Inserm U1153, Paris Descartes University, Paris
[14] Clinical Research Unit, Center for Clinical Investigation P1419, Cochin Broca Hôtel-Dieu Hospital, Paris
[15] Université Paris-Dauphine, PSL-Research University, LEDa, Paris
[16] Institut de Santé Publique, Pôle Recherche Clinique, Institut National de la Santé et de la Recherche Médicale, Paris
[17] Inserm, Institut Thématique Santé Publique, Paris
[18] IRIS, Inserm/EHESS/CNRS, Aubervilliers
[19] Department of Statistics, Computer Science and Applications, University of Florence, Florence
关键词：
Cohort;
COVID-19;
General population;
Risk factors;
SARS-CoV-2;
Seroprevalence;
D O I：
10.1093/ije/dyab173
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ;
120402 ;
摘要：
Background: We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors. Methods: Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies. Results: The analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI): 9.1%, 10.9%] and 11.4% (95% CI: 10.1%, 12.8%) in IDF, 9.0% (95% CI: 7.7%, 10.2%) and 9.8% (95% CI: 8.1%, 11.8%) in GE and 3.1% (95% CI: 2.4%, 3.7%) and 2.9% (95% CI: 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI: 1.79, 6.09) in <40 vs 50-60 years old and OR = 0.56 (95% CI: 0.42, 0.74) in ≥70 vs 50-60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI: 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI: 0.57, 0.89)]. Conclusions: Seropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified. © 2021 The Author(s) 2021; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.
引用
收藏
页码：1755 / 1755
页数：1
相关论文